2026-06-14T03:54:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/113502024-11-29T13:44:58Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Colomer, Ramon author Mondejar, Rebeca author Romero-Laorden, Nuria author Alfranca, Arantzazu author Sanchez-Madrid, Francisco author Quintela Fandino, Miguel Angel author colomer author 2020-08 Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice. EClinicalMedicine. 2020 ;25:100487. 10.1016/j.eclinm.2020.100487 EClinicalMedicine 32775973 http://hdl.handle.net/20.500.12105/11350 PRECISION ONCOLOGY PERSONALISED MEDICINE NEXT GENERATION SEQUENCING cANCER GENOMICS CANCER THERAPY TARGETED THERAPY When should we order a next generation sequencing test in a patient with cancer?